NCT06623032 Metabolic Effects of Medium-Chain Fatty Acids in Patients With Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Healthy Individuals
| NCT ID | NCT06623032 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Copenhagen |
| Condition | Medium-chain Acyl-CoA Dehydrogenase Deficiency |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-10-18 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-10-18 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this project is to investigate the physiological effects of intake of long-chain fatty acids (LCFA) and medium-chain fatty acids (MCFA) in patients with Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) and healthy individuals
Eligibility Criteria
Inclusion Criteria MCADD patients: * Male or female * Age between 18-80 years old * Diagnosed Medium-chain acyl-CoA dehydrogenase deficiency (MCADD Inclusion Criteria Healthy Participants: * Male or female * Age between 18-80 years old Exclusion Criteria both MCADD patients and healthy participants: * Diabetes * Kidney- or liver disease * Use of beta blockers or diuretics * Pregnant, lactating or planning to become pregnant within the study period * Regular intake of substantial amounts of coconut oil, palm kernel oil or any other source abundant in MCFA * Ongoing cancer treatment * Metabolic or absorptive disorders, gastric bypass operation, or use of medication affecting metabolism or food absorption * Inability, physically or mentally, to comply with the procedure required by the study protocol as evaluated by the primary investigator, study manager or clinical responsible
Contact & Investigator
Andreas M Fritzen, Associate Professor
PRINCIPAL INVESTIGATOR
University of Copenhagen
Frequently Asked Questions
Who can join the NCT06623032 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Medium-chain Acyl-CoA Dehydrogenase Deficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06623032 currently recruiting?
Yes, NCT06623032 is actively recruiting participants. Contact the research team at kaspersuhr@sund.ku.dk for enrollment information.
Where is the NCT06623032 trial being conducted?
This trial is being conducted at Copenhagen, Denmark.
Who is sponsoring the NCT06623032 clinical trial?
NCT06623032 is sponsored by University of Copenhagen. The principal investigator is Andreas M Fritzen, Associate Professor at University of Copenhagen. The trial plans to enroll 30 participants.